A Phase 2/3 interventional study of ATH-1017 and Placebo in Alzheimer Disease and Dementia of Alzheimer Type, sponsored by Athira Pharma. Completed at 1 site in United States. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by Athira Pharma · Phase 2/3, Interventional, and Treatment
Among 1,939 studies in Alzheimer Disease with a site in United States — 345 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,939 studies in Alzheimer Disease with a site in United States, this one is the 169th largest by enrollment of the 1,608 interventional ones that give a count, is one of 104 that started in 2020, is one of 42 in phase 2/3, and was the 1,222nd registered.
3,967 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →345 of the 1,939 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 642 Alzheimer Disease studies recruiting now, 283 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 284 take healthy volunteers.
This study: 55 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,939 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 104 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 554 is above the median of 70 across 3,020 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,608 interventional studies, 160 across the 309 observational. Of the 1,377 that completed or were terminated, 590 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,939 have an industry lead sponsor. The 10 most frequent:
Athira Pharma is the lead sponsor of 8 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Athira Pharma has 4 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
164 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 164 to your calendar (.ics) → With an account.
Among the 1,939 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease with a randomized treatment duration of 26-weeks.
The study is designed to evaluate safety and efficacy of ATH-1017 in mild to moderate AD subjects, with randomized, parallel-arm treatment duration of 26 weeks, and based on clinical diagnostic criteria of Alzheimer's disease. Clinical efficacy is demonstrated by improvement in cognition and global/functional assessments comparing treatment to placebo.
Key Inclusion Criteria:
Treatment-free (subjects not receiving acetylcholinesterase inhibitor [AChEI] treatment), defined as:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daily subcutaneous (SC) injection of 40mg ATH-1017
Drug: ATH-1017
Daily subcutaneous (SC) injection of Placebo
Drug: Placebo
Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
Global Statistical Test (GST) Score
The Global Statistical Test (GST) score is a composite of cognition and function, calculated as the average of two change from baseline z-scores; the z-scores are calculated for the change from baseline scores for cognition (Alzheimer's Disease Assessment Scale-Cognitive Subscale \[ADAS-Cog11\]; lower value indicates improvement) and function (Alzheimer's Disease Cooperative Study - Activities of Daily Living, 23-item version \[ADCS-ADL23\] score; higher value indicates improvement). GST is a standardized score relative to the population mean. Therefore, a GST score of 0 is representative of the population mean. Since GST is a composite of two endpoints, a negative ADCS-ADL23 score is used in deriving GST. Therefore, a lower score indicates improvement, and a higher score indicates worsening. There are no defined clinically relevant thresholds for this GST score.
Time frame: Baseline and Week 26
Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11) Change From Baseline
The ADAS-Cog11 was designed to measure cognitive symptom change in participants with Alzheimer's Disease (AD) and consisted of 11 tasks. The standard 11 items (and corresponding score range) were: word recall (0-10), commands (0-5), constructional praxis (0-5), naming objects and fingers (0-5), ideational praxis (0-5), orientation (0-8), word recognition (0-12), spoken language ability (0-5), comprehension of spoken language (0-5), word-finding difficulty (0-5), and remembering test instructions (0-5). The test included 7 performance items and 4 clinician-rated items. The ADAS-Cog11 total score was the sum of all 11 individual items, with a total score ranging from 0 (no impairment) to 70 (severe impairment). Higher scores indicated more severe cognitive impairment. Baseline was defined as Day 1.
Time frame: Baseline and Week 26
Alzheimer's Disease Cooperative Study - Activities of Daily Living, 23-Item Version (ADCS-ADL23) Change From Baseline
The ADCS-ADL23 is a 23-item assessment of functional impairment in terms of activities of daily living administered to the support person/caregiver. It comprises 23 questions about the subject's involvement and level of performance across items representing daily living. The questions range from basic to instrumental activities of daily living. Each item is rated from the highest level of independent performance to complete loss. The total score range is from 0 to 78, with lower scores indicating greater functional impairment. Baseline was defined as Day 1.
Time frame: Baseline and Week 26
Plasma Neurofilament Light Chain (NfL) Concentrations Change From Baseline
Neurofilament light chain (NfL) is an objective biomarker of neurodegeneration and was measured to quantitatively support the evaluation of ATH-1017. Higher concentrations of NfL in plasma are associated with neurodegeneration.
Time frame: Baseline and Week 26
The study was conducted in the United States.
| Milestone | Placebo | ATH-1017 40 Milligrams (mg) | ATH-1017 70 mg |
|---|---|---|---|
| Started | 218 | 224 | 107 |
| Completed | 183 | 174 | 69 |
| Not completed | 35 | 50 | 38 |
| Withdrew: Adverse event | 10 | 22 | 18 |
| Withdrew: Withdrawal by subject | 3 | 6 | 1 |
| Withdrew: Lost to follow-up | 0 | 3 | 2 |
| Withdrew: Protocol violation | 2 | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Undetermined | 15 | 9 | 5 |
| Withdrew: >1 reason | 4 | 7 | 12 |
| Milestone | Placebo | ATH-1017 40 Milligrams (mg) | ATH-1017 70 mg |
|---|---|---|---|
| Started | 144 | 143 | 0 |
| Completed | 128 | 122 | 0 |
| Not completed | 16 | 21 | 0 |
| Withdrew: Adverse event | 6 | 9 | 0 |
| Withdrew: Withdrawal by subject | 0 | 4 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Withdrew: Undetermined | 7 | 3 | 0 |
| Withdrew: >1 reason | 2 | 4 | 0 |
The Global Statistical Test (GST) score is a composite of cognition and function, calculated as the average of two change from baseline z-scores; the z-scores are calculated for the change from baseline scores for cognition (Alzheimer's Disease Assessment Scale-Cognitive Subscale \[ADAS-Cog11\]; lower value indicates improvement) and function (Alzheimer's Disease Cooperative Study - Activities of Daily Living, 23-item version \[ADCS-ADL23\] score; higher value indicates improvement). GST is a standardized score relative to the population mean. Therefore, a GST score of 0 is representative of the population mean. Since GST is a composite of two endpoints, a negative ADCS-ADL23 score is used in deriving GST. Therefore, a lower score indicates improvement, and a higher score indicates worsening. There are no defined clinically relevant thresholds for this GST score.
| Z-score | Placebo | ATH-1017 40 Milligrams (mg) |
|---|---|---|
| Global Statistical Test (GST) Score | -0.126 ± 0.0683 | -0.208 ± 0.0707 |
The ADAS-Cog11 was designed to measure cognitive symptom change in participants with Alzheimer's Disease (AD) and consisted of 11 tasks. The standard 11 items (and corresponding score range) were: word recall (0-10), commands (0-5), constructional praxis (0-5), naming objects and fingers (0-5), ideational praxis (0-5), orientation (0-8), word recognition (0-12), spoken language ability (0-5), comprehension of spoken language (0-5), word-finding difficulty (0-5), and remembering test instructions (0-5). The test included 7 performance items and 4 clinician-rated items. The ADAS-Cog11 total score was the sum of all 11 individual items, with a total score ranging from 0 (no impairment) to 70 (severe impairment). Higher scores indicated more severe cognitive impairment. Baseline was defined as Day 1.
| score on a scale | Placebo | ATH-1017 40 Milligrams (mg) |
|---|---|---|
| Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11) Change From Baseline | -0.39 ± 0.54 | -1.09 ± 0.56 |
The ADCS-ADL23 is a 23-item assessment of functional impairment in terms of activities of daily living administered to the support person/caregiver. It comprises 23 questions about the subject's involvement and level of performance across items representing daily living. The questions range from basic to instrumental activities of daily living. Each item is rated from the highest level of independent performance to complete loss. The total score range is from 0 to 78, with lower scores indicating greater functional impairment. Baseline was defined as Day 1.
| score on a scale | Placebo | ATH-1017 40 Milligrams (mg) |
|---|---|---|
| Alzheimer's Disease Cooperative Study - Activities of Daily Living, 23-Item Version (ADCS-ADL23) Change From Baseline | -0.02 ± 0.65 | 0.65 ± 0.67 |
Neurofilament light chain (NfL) is an objective biomarker of neurodegeneration and was measured to quantitatively support the evaluation of ATH-1017. Higher concentrations of NfL in plasma are associated with neurodegeneration.
| picogram / milliter | Placebo | ATH-1017 40 Milligrams (mg) |
|---|---|---|
| Plasma Neurofilament Light Chain (NfL) Concentrations Change From Baseline | 2.95 ± 2.49 | -0.96 ± 2.48 |
Collected over Up to 30 weeks. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/218 (0%) | 15/218 (6.9%) | 65/218 (29.8%) |
| ATH-1017 40 Milligrams (mg) | 0/224 (0%) | 11/224 (4.9%) | 185/224 (82.6%) |
| ATH-1017 70 mg | 0/107 (0%) | 3/107 (2.8%) | 104/107 (97.2%) |
| Event | Placebo | ATH-1017 40 Milligrams (mg) | ATH-1017 70 mg |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 3/218 | 0/224 | 0/107 |
| DiarrhoeaGastrointestinal disorders | 0/218 | 0/224 | 1/107 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/218 | 0/224 | 1/107 |
| AngioedemaSkin and subcutaneous tissue disorders | 0/218 | 1/224 | 1/107 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/218 | 0/224 | 0/107 |
| Atrioventricular block second degreeCardiac disorders | 1/218 | 0/224 | 0/107 |
| Colitis ischaemicGastrointestinal disorders | 1/218 | 0/224 | 0/107 |
| Intestinal obstructionGastrointestinal disorders | 1/218 | 0/224 | 0/107 |
| CholecystitisHepatobiliary disorders | 1/218 | 1/224 | 0/107 |
| CholelithiasisHepatobiliary disorders | 1/218 | 1/224 | 0/107 |
| Event | Placebo | ATH-1017 40 Milligrams (mg) | ATH-1017 70 mg |
|---|---|---|---|
| Injection site reactionsGeneral disorders | 31/218 | 128/224 | 78/107 |
| EosinophiliaBlood and lymphatic system disorders | 0/218 | 16/224 | 8/107 |
| PruritusSkin and subcutaneous tissue disorders | 4/218 | 10/224 | 6/107 |
| COVID-19Infections and infestations | 12/218 | 10/224 | 2/107 |
| FallInjury, poisoning and procedural complications | 9/218 | 10/224 | 5/107 |
| Urinary tract infectionInfections and infestations | 9/218 | 5/224 | 2/107 |
| HeadacheNervous system disorders | 9/218 | 6/224 | 3/107 |
Safety Population: included all randomized participants who received at least one dose of the study medication.
| Age, Continuous(years) | Placebo | ATH-1017 40 Milligrams (mg) | ATH-1017 70 mg | Total |
|---|---|---|---|---|
| Mean | 73.4 ± 7.22 | 72.7 ± 7.24 | 71.0 ± 6.80 | 72.6 ± 7.19 |
| Sex: Female, Male(Participants) | Placebo | ATH-1017 40 Milligrams (mg) | ATH-1017 70 mg | Total |
|---|---|---|---|---|
| Female | 116 | 115 | 56 | 287 |
| Male | 102 | 109 | 51 | 262 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | ATH-1017 40 Milligrams (mg) | ATH-1017 70 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 39 | 45 | 6 | 90 |
| Not Hispanic or Latino | 179 | 177 | 101 | 457 |
| Unknown or Not Reported | 0 | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Placebo | ATH-1017 40 Milligrams (mg) | ATH-1017 70 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 13 | 7 | 1 | 21 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 0 | 2 |
| Black or African American | 14 | 19 | 8 | 41 |
| White | 185 | 194 | 97 | 476 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 2 | 1 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Jul 2024, 45 months.
Results were first posted in Apr 2025, 8 months after primary completion.
Of 28 phase 2/3 interventional studies under Alzheimer Disease, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 59. This study's 45 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fosgonimeton sodium
Athira Pharma